Hisashi Hidaka

Kitasato University School of Medicine
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Aim The aim of this study was to identify clinical factors associated with fecal Streptococcus spp. load in patients with chronic liver disease (CLD) and to evaluate its potential utility, measured through digital polymerase chain reaction (dPCR), as a noninvasive biomarker for liver fibrosis. Methods Data from 146 patients with CLD enrolled in a prospective single‐center cohort were retrospectively analyzed. Fecal Streptococcus spp. load was quantified using dPCR with a 16S rRNA gene primer–probe set. Given the substantial effect of proton pump inhibitor (PPI) use, PPI users were analyzed separately and excluded from fibrosis‐specific analyses. Associations with clinical parameters were examined using Spearman's rank correlation, and receiver operating characteristic (ROC) curve analysis was carried out to evaluate diagnostic performance for cirrhosis. Results Among 146 patients, 45 (30.8%) were PPI users and 101 (69.2%) were nonusers. Median Streptococcus spp. load was significantly higher in PPI users than in nonusers (470.8 vs. 107.8 copies/μL and p 65 years with BMI ≤ 25 kg/m 2 showed higher loads. Conclusions Fecal Streptococcus spp. load measured by dPCR may complement existing noninvasive fibrosis markers in CLD, although host‐related factors, such as age and BMI, may limit diagnostic accuracy.

Year:

2026

Year:

2025

Aim Data on the upregulation of Mac‐2 binding protein (M2BP) expression associated with fat accumulation in the liver are limited. Therefore, we aimed to assess the relationship between hepatic M2BP expression and changes in the liver microenvironment due to fat accumulation in patients with metabolic dysfunction associated steatotic liver disease (MASLD). Methods Liver specimens obtained from 46 patients with MASLD were subjected to immunohistochemical staining to visualize M2BP expression in the liver. The staining intensity in the hepatocytes and sinusoidal cells was classified as high or low grade. First, the correlation between hepatic M2BP expression and microenvironmental changes caused by fat accumulation was examined. Then, the influence of hepatic M2BP expression on serum M2BP glycosylation isomer levels in patients with MASLD was evaluated. Results The staining grade of M2BP was higher in the sinusoidal cells than in the hepatocytes ( p = 0.015). The patients with high staining grade in their hepatocytes had more severe lobular inflammation than those with low staining grade ( p = 0.037). Additionally, the patients with high staining grade in their sinusoidal cells presented more severe fibrosis than those with low staining grade ( p = 0.018). The staining grade in the hepatocytes correlated positively with serum M2BP glycosylation isomer levels ( p = 0.023), whereas no correlation was observed between sinusoidal staining grade and serum M2BP glycosylation isomer levels ( p = 0.393). Conclusions Fat accumulation in patients with MASLD leads to M2BP expression in hepatocytes due to liver inflammation and that in sinusoidal cells due to fibrosis.

Year:

2024

Aim This study aims to evaluate the efficacy and safety of lenvatinib radiofrequency ablation (RFA) sequential therapy for certain hepatocellular carcinoma (HCC) patients. Methods One hundred and nineteen patients with unresectable HCC in the intermediate stage with Child–Pugh A were retrospectively recruited in a multicenter setting. Those in the lenvatinib RFA sequential therapy group received lenvatinib initially, followed by RFA and the retreatment with lenvatinib. The study compared overall survival (OS), progression‐free survival (PFS), tumor response, and adverse events (AEs) between patients undergoing sequential therapy and lenvatinib monotherapy. Results After propensity score matching, 25 patients on sequential therapy and 50 on monotherapy were evaluated. Independent factors influencing OS were identified as sequential therapy, modified albumin–bilirubin (mALBI) grade, and relative dose intensity (%) with hazard ratios (HRs) of 0.381 (95% confidence interval [CI], 0.186–0.782), 2.220 (95% CI, 1.410–3.493), and 0.982 (95% CI, 0.966–0.999), respectively. Stratified analysis based on mALBI grades confirmed the independent influence of treatment strategy across all mALBI grades for OS (HR, 0.376; 95% CI, 0.176–0.804). Furthermore, sequential therapy was identified as an independent factor of PFS (HR, 0.382; 95% CI, 0.215–0.678). Sequential therapy significantly outperformed monotherapy on survival benefits (OS: 38.27 vs. 18.96 months for sequential therapy and monotherapy, respectively, p = 0.004; PFS: 13.80 vs. 5.32 months for sequential therapy and monotherapy, respectively, p < 0.001). Sequential therapy was significantly associated with complete response by modified Response Evaluation Criteria in Solid Tumors (odds ratio, 63.089). Ten of 119 patients experienced grade 3 AEs, with no AE beyond grade 3 observed. Conclusion Lenvatinib RFA sequential therapy might offer favorable tolerability and potential prognostic improvement compared to lenvatinib monotherapy.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Satoshi Kobayashi

Kanagawa Cancer Center

JAPAN
View details

Shin Maeda

-

JAPAN
View details

Yasuhito Tanaka

M.D., Ph.D

Kumamoto University

JAPAN
View details

Kosuke Okuwaki

Kitasato University

JAPAN
View details

Tatehiro Kagawa

Professor

Tokai University School of Medicine

JAPAN
View details

Kota Tsuruya

Tokai University

JAPAN
View details